ArticleMolecules (Basel, Switzerland)2012
Synthesis and protective effect of scutellarein on focal cerebral ischemia/reperfusion in rats.
Article in Molecules (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- Effect of breviscapine on CYP3A metabolic activity in healthy volunteers.European journal of clinical pharmacology · 2018Trial
- Article
- Therapeutic potential of natural products in ischemic stroke: targeting angiogenesis.Frontiers in pharmacology · 2025Review
- Article
- A Multilevel Study of Eupatorin and Scutellarein as Anti-Amyloid Agents in Alzheimer's Disease.Biomedicines · 2023Article
- Neuroprotective Strategies for Stroke by Natural Products: Advances and Perspectives.Current neuropharmacology · 2023Review
- Neuroprotective Effect of Fisetin Against the Cerebral Ischemia-Reperfusion Damage via Suppression of Oxidative Stress and Inflammatory Parameters.Inflammation · 2021Article
- Experimental pretreatment with YES-10Experimental and therapeutic medicine · 2021Article
- Combined Scutellarin and CFrontiers in oncology · 2021Article
- Scutellarin Exerts Anti-Inflammatory Effects in Activated Microglia/Brain Macrophage in Cerebral Ischemia and in Activated BV-2 Microglia Through Regulation of MAPKs Signaling Pathway.Neuromolecular medicine · 2020Article
- CBioMed research international · 2019Article
- Altered expression of thrombospondin-1/-2 in the cortex and synaptophysin in the hippocampus after middle cerebral artery occlusion and reperfusion.International journal of clinical and experimental pathology · 2018Article
- Herbal Compounds Play a Role in Neuroprotection through the Inhibition of Microglial Activation.Journal of immunology research · 2018Review
- Synthesis and Bioactivity Characterization of Scutellarein Sulfonated Derivative.Molecules (Basel, Switzerland) · 2017Article
- Novel Tacrine-Scutellarin Hybrids as Multipotent Anti-Alzheimer's Agents: Design, Synthesis and Biological Evaluation.Molecules (Basel, Switzerland) · 2017Article
- An Efficient Chemical Synthesis of Scutellarein: An in Vivo Metabolite of Scutellarin.Molecules (Basel, Switzerland) · 2016Article
- Article
- Scutellarin attenuates hypertension-induced expression of brain Toll-like receptor 4/nuclear factor kappa B.Mediators of inflammation · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scutellarein, the main metabolite of scutellarin in vivo, has relatively better solubility, bioavailability and bio-activity than scutellarin. However, compared with scutellarin, it is very difficult to obtain scutellarein from Nature. Therefore, the present study focused on establishing an efficient route for the synthesis of scutellarein by hydrolyzing scutellarin. Neurological deficit score and cerebral infarction volume with the administration of scutellarein were then used to compare its neuroprotective effects on focal cerebral ischemia/reperfusion in rats induced by middle cerebral artery occlusion (MCAO) with those of scutellarin. The results showed that scutellarein had better protective effect on focal cerebral ischemia/reperfusion than scutellarin, which laid the foundation for further research and development of scutellarein as a promising candidate for ischemic cerebro-vascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.